Clinical Trial Update: A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the hypotensive efficacy of AR-12286 ophthalmic solution at 0.5% and 0.7% in glaucoma patients with uncontrolled intr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• AR-12286 ophthalmic solution 0.5% (AR-12286)
• AR-12286 ophthalmic solution 0.7% (AR-12286)

Snippet

Sponsor: New York Glaucoma Research Institute | Conditions: Glaucoma | Phase 2 | Status: UNKNOWN